Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
Provided By GlobeNewswire
Last update: May 12, 2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025
Read more at globenewswire.com30.88
+0.74 (+2.46%)
Find more stocks in the Stock Screener
MTSR Latest News and Analysis
